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Bacteria and archaea employ an adaptive immune system in the form of clustered 
regularly interspaced short palindromic repeats (CRISPR) to fend off mobile genetic 
elements. CRISPR arrays store immunological memory in the form of spacer sequences 
flanked by repeat sequences, where the array is preceded by a leader sequence to regulate 
the placement of acquired protospacers. CRISPR-associated (Cas) proteins generate and 
carry out the immune response against invading genetic elements. 
Categorized as a Class I CRISPR system, Type III systems are further divided 
into Type III-A (Csm) and III-B (Cmr) which utilize multisubunit complexes to target 
and cleave DNA. The Cmr complex binds and cleaves RNA transcripts to activate its 
DNA cleavage activity. The goal of obtaining a cryo-EM structure of the Cmr complex is 
to determine how target RNA binding activates DNase activity, as the target binding site 
and the DNase active site are distant from each other. 
The Thermotoga maritima Cmr2 – 6 complex was purified by pooling together 
cells expressing each subunit and lysing by microfluidizer, followed by immobilized 
metal ion affinity (IMAC) and size exclusion chromatography. The Cmr2:3 heterodimer 
was purified in a similar manner, with additional desalting and polyhistidine (His) tag 
cleavage steps after IMAC elution. Purification of the Cmr complex produced 180µg of 
protein, and purification of Cmr2:3 yielded 7mg of protein. Crystallization trays were set 
up with the purified Cmr2:3 sample, and the Cmr2 – 6 complex was incubated with Cmr1 
and CRISPR RNA to form the full interference complex. 500µm crystal florets formed in 
the Cmr2:3 crystallization trays, but x-ray diffraction determined that Cmr3 alone formed 
the crystals. The Cmr complex incubation mixture was separated by analytical size 
 iii 
exclusion, and the monodisperse peak corresponding to the correct number of subunits 
was recovered for cryo-EM analysis.   
The disruption in Cmr2:3 crystallization was thought to be a result of the His tag 
interfering with the crystal packing of the heterodimer, and new crystallization trays were 
set up with tag-cleaved Cmr2:3. The full Cmr complex was also successfully formed, but 
the bound RNA needs to be analyzed to determine whether it is intact after full complex 
formation. 
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 Humans utilize an immune system to fend off foreign infections by viruses and 
bacteria using an innate immune response upon initial infection, and a memory-based 
adaptive immune response upon subsequent infections by the same microbe. 90% of 
sequenced archaea and 40% of sequenced bacteria also employ a similar type of immune 
system against mobile genetic elements using clustered regularly interspaced short 
palindromic repeats (CRISPR). CRISPR arrays store immunological memory in the form 
of spacer sequences flanked by repeat sequences, where the array is preceded by a leader 
sequence to regulate the placement of acquired protospacers from mobile genetic 
elements. CRISPR-associated (Cas) proteins generate and carry out the adaptive immune 
response against invading genetic elements.  
 
CRISPR Components 
 CRISPR immunity is subdivided into two classes, composed of numerous 
subtypes each with its own distinct interference mechanism and molecular composition. 
Interference is the mechanism of CRISPR response where ribonucleoprotein single/multi-
subunit complexes composed of Cas proteins surveil the intracellular environment guided 
by bound CRISPR RNA (crRNA) and cleaves foreign DNA that anneal to the crRNA. 
Class I CRISPR systems utilize a multi-subunit interference complex composed of 
numerous Cas proteins, crRNA, and includes Type I, III, and IV systems (Figure 1). 
Class II CRISPR systems utilize a single subunit interference complex composed of one 
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Cas protein with crRNA, held together by a structural transactivating CRISPR RNA 
(tracrRNA) in the Type II subtype. Protospacers are the sequences of foreign DNA that 
are excised by Cas proteins and integrated into the host CRISPR array, and therefore are 
the target sequences for CRISPR interference. CRISPR RNA is composed of a single 
spacer sequence flanked by truncated repeat sequences, which is used as the guide to 
selectively target mobile genetic elements that forms base complementarity to the 
protospacer sequence. Type I, II, and V systems utilize short 2-5 nucleotide sequences 
that flank the protospacer in foreign DNA called protospacer adjacent motifs (PAMs) as 
markers for distinguishing between self and nonself DNA (Wang et al., 2015). During 
acquisition of spacer sequences, spacers are preferentially selected from protospacers that 
contain a cognate PAM to that CRISPR system(Mojica et al., 2009). Other CRISPR types 
use other mechanisms to avoid autoimmunity, such as the Type III systems utilizing the 
flanking sequences of the RNA transcript to determine whether the DNase activity of 
Cas10-like Cmr2 will be turned on or off (Marraffini and Sontheimer, 2010). Acquisition 
is a process that involves the excision of protospacers from foreign DNA and the 
integration of the protospacers into the host CRISPR array. Acquisition components are 
conserved across all classes and subtypes, and features Cas1, Cas2, the CRISPR array 
leader sequence, and the first repeat sequence after the leader sequence. Cas1 exhibits 
nuclease activity and inserts new spacers in the CRISPR array between the leader 
sequence and the first repeat, with the leader sequence being a long A:T-rich sequence 
oriented immediately upstream of the CRISPR array, containing both the crRNA 






Figure 1: Pathway of Class I CRISPR system response (Samson et al., 2013)  
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Mechanism of Acquisition 
Upon invasion by foreign DNA, the host CRISPR system needs to distinguish the 
incoming DNA as self vs nonself before acquisition is initiated. A sequence of 30-40 
base pairs needs to be obtained from the foreign DNA, which will serve as a protospacer 
for insertion into the host CRISPR array. Two types of adaptation have been determined 
in Type I systems, the first of which is naïve acquisition which takes place upon 
encounter with a new invading genetic element, whereas primed acquisition occurs if the 
invading phage mutates their PAM or protospacer sequence in attempts to evade 
interference (Datsenko et al., 2012). Naïve adaptation utilizes only Cas1 and Cas2, 
whereas primed adaptation also requires the Cascade interference complex as well as the 
Cas3 endonuclease. Cas3 is composed of a histidine-aspartate (HD) domain that exhibits 
DNase activity, which is fused to a helicase domain that unwinds dsDNA in an ATP-
dependent manner. The necessity of Cas1 in general spacer acquisition was confirmed by 
Babu et al. by generating the nuclease-deficient Cas1 D221A mutant and demonstrating 
that the construct did not support spacer acquisition in vivo (Babu et al., 2011). Naïve 
adaptation in Type II systems however require Cas9 to recognize PAMs in comparison to 
Type I-E systems where only Cas1 and Cas2 are needed for detection of PAMs. Primed 
adaptation on the other hand does not occur unless Cas1, Cas2, Cas3, Cascade, and the 
priming spacer are present (Datsenko et al., 2012). Type I-E systems utilize priming to 
amplify acquisition ten- to twenty-fold over naïve adaptation, and is biased towards the 
strand orientation that matches the protospacer that is targeted by the priming spacer 
(Savitskaya et al., 2013). Datsenko et al. postulated that priming likely evolved as a 
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mechanism of avoiding infection by phage escape mutants that would otherwise evade 
interference by CRISPR, as priming efficiency is markedly increased when the priming 
spacer was mutated in the seed sequence or if the protospacer contained a non-cognate 
PAM (Datsenko et al., 2012). Single-molecule experiments have also shown that non-
canonical Cascade binding modes exist at mutated protospacers and could be crucial to 
the primed adaptation mechanism as protospacers with mutated PAMs can still elicit 
stable Cascade binding. These results coupled with the identification of specific 
intermolecular Cascade:Cas3 interactions shows that recognition of a consensus PAM by 
Cascade is necessary for functional recruitment of Cas3 to promote interference (Blosser 
et al., 2015).  
 
RecBCD: Protospacer Source 
RecBCD is an exonuclease complex that recognizes exposed dsDNA from 
double-stranded breaks in E. coli, which it then unwinds and degrades until it reaches an 
8bp crossover hotspot instigator (Chi) site. Hotspots for protospacers are situated 
between the stall sites of replication forks, a major source of double-stranded breaks, and 
the closest Chi site (Ivancic-Bace et al., 2015). Chi sites appear frequently in the E. coli 
genome, typically occurring every 4.6 kilobases (kb) compared to 65kb if the sites were 
to appear by chance in a genome. The frequency of Chi sites allows for only short lengths 
of host DNA to be degraded by RecBCD before it reaches the next Chi site, which yields 
very few potential spacers that arise from degradation products of host DNA (Levy et al., 
2015). This observation when applied to foreign DNA that are not enriched in Chi sites 
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will result in longer stretches of DNA degradation by RecBCD, yielding a greater number 
of viable protospacers for integration. Since phage/viral DNA enter hosts as linear 
dsDNA, the linear ends are recognized by RecBCD as double-stranded breaks which 
promotes the degradation of the foreign DNA until RecBCD reaches the next Chi site in 
the sequence. The Cas1:2 heterohexamer along with RecBCD obtain the protospacer 
from the foreign DNA and integrates it as a spacer in the CRISPR array after duplication 
of the flanking repeat sequence (Nunez et al., 2014). Testing by Yosef et al. of repeats by 
sequencing of the duplicated repeat showed that the newly inserted repeat is identical to 
the repeat that is proximal to the leader sequence. Spacers are added to the array in a 
polar manner, orienting towards the leader sequence side of the array where the most 
recently-incorporated spacer is proximal to the leader sequence (Yosef et al., 2012). E. 
coli protospacers containing a flanking 5’-AAG-3’ PAM are selected as donors with a 
35% frequency, which is overrepresented compared to the frequency of PAMs in general, 
which is roughly 1.6%. Protospacers of varying GC content did not appreciably affect the 
efficiency of acquisition, but an AA motif at the end of the protospacer did increase the 
efficiency of adaptation (Fineran et al., 2014).  
 
 
Acquisition Mechanism: Adaptation 
Mechanistically, naïve adaptation requires DNA substrates that contain the 3’-OH 
that is needed for nucleophilic attack on both strands of the repeat. The Cas1:2 
heterohexamer integrates new spacers with the correct orientation of the PAM by 
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utilizing the 3’-OH cytidine that is complimentary to the third residue of the AAG PAM 
(Pougach et al., 2010). Regulation of adaptation is crucial to prevent the acquisition of 
self spacers that would lead to cell death, and thus transcription-dependent regulators of 
CRISPR interference exists in several systems such as the E. coli Type I-E cyclic AMP 
receptor protein regulator and the histone-like nucleoid-structuring protein (H-NS) 
(Pougach et al., 2010). H-NS suppresses the operon promoter that is composed of the 
Cascade, Cas1, Cas2, and transcription regulation genes of the CRISPR array. Because of 
this, H-NS reduces adaptation by repressing the promoter of the cas gene operon. The 
redundancy in PAM recognition serves to enhance the specificity of spacer acquisition 
using consensus PAMs during primed adaptation over naïve adaptation (Savitskaya et al., 
2013). Experiments on naïve adaptation have shown that Cas1 and Cas2 of Type I-E 
systems prefer spacers from plasmids as opposed to chromosomal DNA, despite the 
excess of chromosomal DNA available to Cas1 and Cas2, which is due to the inherent 
selectivity for foreign DNA during the adaptation process as opposed to selective 
pressures against acquisition of chromosomal spacers (Yosef et al., 2012). A major 
mechanism of preference for foreign DNA reveals spacer acquisition hotspots upstream 
of replication stalling (Ter) sites, which stall the faster-moving replication forks during 
bidirectional DNA replication until the lagging replication fork finishes replication to 
allow for chromosome decatenation (Levy et al., 2015). Additional hotspots for spacer 
acquisition include DNA nicks and double-stranded breaks that also stall replication forks, 
which are targeted by RecBCD for degradation until it reaches the next Chi site. This 
suggests that spacer acquisition occurs most frequently from regions of DNA that 
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undergo frequent replication stalls, and the high copy number of plasmids results in a 
greater occurrence of termination events in comparison to chromosomal replication. 
 
Structural Mechanism of Cas1-Cas2 Function 
Structurally, interactions between N-terminal domains of adjacent Cas1 protomers 
promotes stable homodimerization of Cas1 (Nunez et al., 2015). Three highly-conserved 
C-terminal residues (E141, H208, and D221 in E. coli) coordinate divalent metal ions to 
form the putative active site of Cas1, and mutation of any of these residues results in 
complete elimination of observable nuclease activity. Cas2 possesses a highly-conserved 
architecture composed of a single domain and a ferredoxin-like fold that is also found in 
Cas5 and Cas6, and readily forms a stable homodimer like in Cas1 (Nunez et al., 2015). 
E. coli Cas1:2 forms a heterohexamer architecture with pseudo-two-fold symmetry 
containing a central Cas2 dimer that interacts on two opposing faces with separate Cas1 
dimers. The Cas1:2 interface is stabilized by electrostatic and hydrophobic interactions, 
and interference of this interface results in perturbation of complex formation in vitro and 
spacer acquisition in vivo. Binding between CRISPR DNA and Cas1 is dependent upon 
the presence of Cas2, but acquisition was completely inhibited by Cas1 active site 
mutations (Nunez et al., 2014). This suggests that the primary role of Cas2 involves the 
repositioning of Cas1 in the heterohexamer complex as opposed to exhibiting specific 
nuclease activity. The Cas1:2 heterohexamer binds splayed dual-fork DNA substrates 
where 23 bases of dsDNA are flanked by 3’ single-stranded overhangs that thread into 
two Cas1 active sites. Tyrosine-22 of the Cas1 monomers brace the double-stranded 
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region via stacking interactions, which defines the “caliper” role of Cas1:2 to accurately 
measure the length of new spacers, as well as functioning as wedges to generate junctions 
between single-stranded and double-stranded regions of DNA (Wang et al., 2015). Cas1 
specifically targets the 5’-CTT-3’ PAM complementarity sequence within the 3’ single-
stranded overhang region of a donor spacer, which helps position the phosphodiester 
bond after the C1 base to the active site of Cas1 to allow for trimming of spacer 
precursors to the correct length.  
 
Mechanism of Guide RNA Biogenesis 
To determine interference targets, CRISPR systems require guides which are 
transcribed from CRISPR arrays. Upon addition of protospacers into the CRISPR array, 
the array is then transcribed as a precursor crRNA (pre-crRNA) containing all the spacers 
in the array. Depending on the system subtype, the pre-crRNA is matured in one or two 
stages; in Type I and III systems, a Cas6-family endoribonuclease cleaves the pre-crRNA 
within the repeat regions to yield single spacers flanked by incomplete repeat sequences 
(Carte et al., 2010). Cas6 nucleases cleave the pre-crRNA by hydrolyzing an individual 
phosphodiester bond in the repeats of transcripts, resulting in crRNAs that contain a 
complete spacer flanked by an 8 nucleotide 5’ handle derived from repeats, and a 3’ 





Cas6-mediated RNA Processing 
Of the three known processing endonucleases Cas6, Cas6e, and Cas6f, each share 
very little sequence homology but instead share similar three-dimensional structures that 
exhibit ferredoxin folds as RNA recognition motifs (RRMs), where RNA-bound Cas6f 
contains a single ferredoxin fold while Cas6e and Cas6 both contain tandem ferredoxin 
folds. Biochemically, Cas6 homologs are metal-independent endoribonucleases that 
cleave pre-crRNA to generate crRNAs that have a 5’ hydroxyl and either a cyclic 2’-3’ 
phosphate or a 3’ phosphate (Wang et al., 2011). Of the identified CRISPR 
endoribonucleases, they all share the same nucleolytic activity of cleaving 8 nucleotides 
upstream of the repeat sequence junction. CRISPR repeat RNA that are cleaved by 
Pseudomonas aeruginosa Cas6f contain palindromic sequences that form stable hairpin 
loops that are directly upstream of the cleavage site. Cas6f then interacts specifically with 
the RNA hairpin to position the cleavage site at the base of the hairpin, which is also 
demonstrated in E. coli Cas6e (Brouns et al., 2008) but not in Pyrococcus furiosus Cas6 
as it clamps onto nucleotides 2-9 of the repeat RNA through its two ferredoxin-like folds 
(Kunin et al., 2007). The Cas6-anchored 5’ end of the repeat RNA tethers the cleavage 
site between nucleotides 22 and 23 to the Cas6 active site (Wang et al., 2011). While 
sequences proximal to the cleavage site are important for Cas6 cleavage activity, the 
distal sequences near the 5’ terminus of the repeat RNA are also necessary for Cas6 
binding (Figure 2). A notable finding is that recognition of CRISPR RNAs by Cas6 
occurs at a site that is distal to the crRNA cleavage site, and superimposition of the RNA-
bound and RNA-free Cas6 structures shows that helix α2 containing the catalytic His46 
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residue is rotated 6° toward helix α1 in the RNA-bound structure, and this shift 
demonstrates that RNA binding induces changes in the Cas6 catalytic region positioned 
at the opposite side of the protein. Tyrosine-31, histidine-46, and lysine-52 compose the 
catalytic triad of P. furiosus Cas6, as substitution mutations results in inhibition of 
detectable RNAse activity without hindering RNA binding (Carte et al., 2010). 
Substitution of CRISPR repeat RNA nucleotides 25-30 downstream of the cleavage site 
does not interrupt binding by Cas6 but will prevent cleavage as nucleotides U25 and G26 
are crucial for cleavage. The unobserved region of repeat RNA between nucleotide 10-22 
that binds to the crRNA-recognition interface of Cas6 is lined with positive electrostatic 
potential and passes over G-rich loop that is specific to Cas6. Substitution mutations of 
glycine 223, 225, 231, and 233 to alanine resulted in complete inhibition of RNAse 





Figure 2: beads-on-a-string model of crRNA binding to Cas6, with 5' terminus of crRNA 
needed for wrap-around binding (Wang et al., 2011)  
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CRISPR RNA Processing 
In Type II systems, the pre-crRNA base pairs with tracrRNA to form an RNA 
heteroduplex which is then processed by RNase III in the presence of Cas9 (Deltcheva et 
al., 2011). Upon transcription and maturation of the guide RNAs, they are then associated 
with their single- or multi-subunit CRISPR interference complex depending on the 
system subtype. After the crRNA are transferred to the interference complexes, the 3’ 
handles of the crRNA become accessible for trimming by nucleases. In Type I-A, I-B, I-
C, and I-D systems, the product of nucleolytic trimming contains shorter 3’ handles, 
whereas differential trimming in Type III systems yield two mature crRNAs that differ by 
6 bases (Staals et al., 2014).  
 
Mechanism of Interference 
In Type I systems, interference requires recognition of a PAM sequence in the 
invading DNA as well as annealing to the crRNA of the multisubunit Cascade 
interference complex to form an R-loop composed of the double-stranded DNA target 
hybridizing with the single-stranded crRNA, forming a loop from the displaced non-
complementary DNA strand (Westra et al., 2012). Upon satisfying these criteria, Cascade 
then undergoes a conformational change to recruit the Cas3 endonuclease for complete 
cleavage of the invading DNA in the 3’ to 5’ direction (Sinkunas et al., 2011). For Type I 
systems to successfully interfere foreign DNA, base pairing between the seed sequence of 
crRNA and the complementary protospacer is crucial at positions most proximal to the 
PAM, which constitutes nucleotides 1-5 and 7-8 at the 5’ end of the crRNA in Type I-E 
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systems (Semenova et al., 2011). Incomplete base pairing with the seed sequence, as 
demonstrated by mutant targets, results in evasion of Cascade interference. Upon PAM 
recognition and complete annealing of the crRNA seed sequence to the complementary 
DNA target, dsDNA cleavage occurs in an ATP-dependent manner.  
Type II systems utilize Cas9 in complex with tracrRNA and crRNA to interfere 
foreign DNA in a PAM-dependent manner through its RuvC-like and HNH endonuclease 
domains (Gasiunas et al., 2012). The recognition of PAMs in Cas9 is governed by two C-
terminal tryptophan-containing loops of the nuclease domain, and substitution of these 
residues negatively affects binding and cleavage of target DNA. Finding protospacer 
sequences that are complementary to the crRNA involves surveillance of the foreign 
DNA and annealing at a 7-8 nucleotide seed sequence of the crRNA and the 
complementary protospacer, which promotes extended base pairing along the rest of the 
crRNA sequence and causes an R-loop structure to form which results in a 
conformational change to the interference complex to activate intrinsic nuclease activity 
in Type II and III-B systems (Reeks et al., 2013). 
In Type III systems, the interference complex is similar to Cascade in Type I but 
it does not exclusively target foreign DNA as it also targets phage mRNA as well, where 
processive cleavage of the RNA target occurs in 6 nucleotide intervals in the 3’ to 5’ 
direction (Deng et al., 2013). The RNase activity of the Cmr4 subunits is implicated in 
the regularity of cleavage patterns of Cmr interference complexes. Pyrococcus furiosus 
type III-B Cmr complexes re-formed with single crRNAs will cleave target RNAs in 
specific six nucleotide intervals within the region of crRNA complementarity; with four 
 15 
cleavage events occurring using 45-nucleotide crRNAs and three cleavage events 
occurring using 39-nucleotide crRNAs (Hale et al., 2014). Efficiency of target RNA 
cleavage decreases when the crRNA length is reduced to 20 nucleotides, because of 
reduced RNA hybridization between the crRNA and the target RNA or from less efficient 
Cmr complex formation. As crRNA length is shortened from the 3’ terminus, the number 
of cleavage events occurring at the 5’ terminus of the target RNA are gradually lost (Hale 
et al., 2014). The number of cleavage events performed by the Cmr complex can be 
increased by elongating the guide sequence; extending the 45-nucleotide crRNA guide 
region by 22 nucleotides results in four additional cleavage events occurring on the target 
RNA at regular 6 nucleotide intervals.  
RNA cleavage activity of Streptococcus thermophilus Type III-A Csm functions 
similarly to Cmr in that cleavage occurs at 6 nucleotide intervals through the multimeric 
Csm3 subunit, as well as requiring divalent metal cations to exhibit RNase activity. S. 
thermophilus Csm3 contains a well-conserved RNA recognition motif at its core and the 
conserved aspartate-33 residue has been confirmed through mutagenesis to be a critical 
element in the RNA cleavage activity of Csm. Although S. thermophilus Csm requires 
target RNA sequence complementarity for cleavage to occur, there is no detriment to 
cleavage activity if unpaired flanking sequences or PAMs are included in the protospacer, 





Type III CRISPR Systems 
Categorized as a Class I CRISPR system, Type III systems are further divided 
into Type III-A and III-B which utilize the multisubunit Csm (Type III-A) and the Cmr 
(Type III-B) complexes to bind and cleave DNA. The six types of subunits in Type III 
systems share structural homology (Figure 3) with Cmr1 having no homologs in Csm. 
There are no current complete structures of the Csm complex in any organism, but there 
are cryo-EM structures of the Thermus thermophilus Cmr complex by the Doudna group 
(Taylor et al., 2015) and crystal structures of hybrid Pyrococcus furiosus/Archaeoglobus 
fulgidus Cmr complex (Osawa et al., 2015). All published structures of the Cmr complex 
contain truncated Cmr2 subunits that are missing the HD domain that mediates DNase 
activity of the complex as it was found that the domain was not necessary for 
crystallization of the complex, so there are no current published structures of the intact 
Cmr complex in any studied organism (Figure 4). The HD domain exhibits the DNase 
activity of the complex but the DNA binding site is distal to the HD domain, and little is 
known how the binding of DNA activates the DNase activity of Cmr. The Doudna group 
have demonstrated that binding of the DNA target induces an overall conformational 
change in the Thermus thermophilus Cmr complex, and this finding contributes to the 
search for a structural mechanism for DNase activation upon binding of DNA (Taylor et 

















5' Large Subunit Csm1 83 2100 Cmr2 93.5 2400 
5' crRNA Capping 
Subunit Csm4 33 876 Cmr3 37.9 990 
Major Filamenting 
Subunit Csm3 27.5 741 Cmr4 32.8 864 
Minor Filamenting 
Subunit Csm2 16.7 420 Cmr5 14.6 360 
3' Terminal 
Capping Subunit Csm5 44 1100 Cmr1 50.2 1326 
3'-crRNA-
associated Subunit Csm3 27.5 741 Cmr6 27.9 720 
 




Figure 4: (From left to right) Left: model of Pfu Cmr complex (PDB ID: 3X1L) aligned 
with full-length Cmr2 (dark purple, PDB ID: 4W8Y) with HD domain (light pink). 
Center: Pfu Cmr2 full length (dark and light purple) superimposed with truncated Pfu 
Cmr2 (pink) in complex with Cmr3 (green) (PDB ID: 4H4K). Right: published cryo-EM 
reconstruction of Tth apo-Cmr complex with bound crRNA at 4.1Å (Taylor et al., 2015) 
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The Type III interference complexes bind and cleave RNA transcripts to activate 
their DNA cleavage activity (Zhang et al., 2012). The Csm and Cmr complexes binds and 
cleaves ssRNA targets in a divalent metal ion-dependent manner, and they both target 
DNA in a transcription-dependent manner in vivo (Samai et al., 2015). The architecture 
of Type III interference complexes are structurally similar in distribution, with the Type 
III-B Cmr2 and Cmr3 heterodimer (Csm1 and Csm4 in Type III-A systems) situated at 
the 5’ handle of the crRNA. Four subunits of Cmr4 align along the sequence of the 
crRNA, whereas there are six subunits of Csm3 that are positioned along the crRNA, and 
three subunits of either Cmr5/Csm2 face opposite of the multimeric Cmr4/Csm3 (Taylor 
et al., 2015). Cmr1 and Cmr6 associate with the 3’ terminus of the crRNA, whereas in 
Csm complexes there is only a single Csm5 associated with the 3’ terminus. Cmr1 and 
Cmr6 form a cap on the 3’ terminus of the complexed crRNA to mediate crucial 
interactions with the 5’ terminus of the RNA substrate (Tamulaitis et al., 2014). The 
primary DNase activity is exhibited in the large subunits of the interference complexes, 
which are Csm1 and Cmr2, both featuring an HD domain.  
Transcription is required to enter the lysogenic cycle of phage infection, and if 
transcription occurs through a protospacer region the nascent phage mRNA emerging 
from the transcription complex is targeted by Csm or Cmr (Goldberg et al., 2014). In 
order to avoid autoimmunity, measures must be taken to avoid targeting host DNA such 
as PAM targeting in Type I systems. Type III interference complexes are 
transcriptionally-coupled, and thus a mechanism of distinguishing self vs nonself targets 
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is required as the transcription of host anti-CRISPR sequences need to evade interference 
to avoid autoimmunity (Marraffini et al., 2010).  
Formation of a Type III-B ribonucleoprotein complex with crRNA can occur in 
the absence of Cmr1 and Cmr6, but Cmr2-5 are all necessary for complete binding of the 
crRNA (Hale et al., 2014). UV light-induced RNA-protein crosslinking experiments have 
also demonstrated that the crRNA-binding interference complex formed with only Cmr2-
5 possesses an organization that is identical to the full Cmr1-6 complex. The crosslinking 
experiments have also found that Cmr2, Cmr3, and Cmr4 were crosslinked to the fully-
labeled crRNA, demonstrating that these subunits make direct contacts with the crRNA 
in the complex (Hale et al., 2014). Cmr3 crosslinks formed with the nucleotides in the 5’ 
tag of the full-length crRNA as well as the eight nucleotide RNA tag itself without the 
guide sequence or 3’ tail, whereas Cmr2 and Cmr4 only crosslinked to guide sequence 
nucleotides. Cmr2 crosslinking with the 5’-proximal region of the crRNA occurs 
alongside Cmr4 crosslinking along the span of the guide sequence that results in a 
reduction of crosslinking signal at the 3’ terminus of the crRNA. While Cmr5 does not 
form any crosslink patterns with the crRNA, it is still necessary for the formation of the 
RNP complex with the other three necessary Cmr subunits (Spilman et al., 2013).  
Native gel mobility shift assays have demonstrated that Cmr complex formation 
requires the 5’-OH and the 5’ tag sequence of the crRNA, where substitution or deletion 
of the 5’ tag sequence impairing binding of the crRNA by Cmr2-5. Substituting either all 
eight nucleotides or the first two nucleotides of the 5’ tag sequence prevents assembly of 
the Cmr interference complex, and this is also seen in single nucleotide additions to the 5’ 
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end of the tag as well as altering of the 5’-OH to a 5’-phosphate group (Hale et al., 2014). 
On the other hand, mutation of the 3’ terminal sequence of the crRNA from the in vivo 
3’-phosphate to a 3’-OH did not appreciably influence Cmr2-5 binding to the crRNA. 
Synthesized RNAs composed of only eight nucleotide repeats of the 5’ tag sequence 
forms the Cmr complex with identical affinity compared to wild type full-length crRNA, 
with Cmr3 being the only subunit making direct contacts with the 5’ tag sequence in 
absence and in the presence of the guide region of the crRNA. This indicates that Cmr1 
and Cmr6 are crucial for target RNA binding, where elimination of any of the six 
subunits of a full RNA-binding Cmr interference complex results in significant inhibition 
of observed binding to the target RNA. Cmr3 identifies the crRNA sequence motif on its 
own, but requires protein-protein interactions within a complex that includes Cmr2, Cmr4, 
and Cmr5 for optimal binding activity to the crRNA (Taylor et al., 2015).  
Cmr3 of the Cas5 superfamily makes direct contacts with the 5’ terminal tag of 
crRNAs and plays a crucial role in crRNA recognition, as demonstrated from crystal 
structures of the Cas5 homolog in Type I-E interference complexes containing bound 
crRNA exhibiting base-specific contacts between the 5’ tag and residues of Cas5 (Shao et 
al., 2013). This phenomenon play an important and well-conserved role in crRNA 
recognition and complexing in Type I and III systems. A large fraction of processed 
RNAs found in prokaryotes feature a 5’-phosphate termini, but Cas6 CRISPR transcript 
cleavage products include 5’-OH groups instead which are a distinguishing feature of 
crRNA from other processed prokaryotic RNA (Carte et al., 2008). The 5’-OH end of 
processed crRNAs are crucial for the successful discrimination between incorporation of 
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crRNA and the potentially lethal incorporation of host RNAs onto CRISPR interference 
complexes.  
 
CRISPR in Public Health: Drug Discovery 
CRISPR technology is lauded for its precision and applicability in 
excision/insertion of genetic elements across a vast variety of hosts and systems, and such 
is the reason why CRISPR has gained so much attention from media and researchers 
alike. One type of application of CRISPR systems is in drug discovery, where molecular 
biology processes can be manipulated using CRISPR to aid in narrowing down potential 
therapeutic candidates (Shi et al., 2015). One such process is using isogenic knockouts to 
allow for swift establishment of causal roles for tumor suppressors, oncogenes, and other 
genetic factors in a particular disease of interest, demonstrated by Shi et al. through 
screening of protein domains. Homology-dependent repair (HDR) can induce knock-ins 
of mutant alleles to test the effects of disease-associated mutations in an isogenic 
environment, and CRISPR-Cas9 could be used to mediate gene knock-outs to facilitate 
testing of synthetic lethality in a drug candidate for tumor cells. Establishment of 
isogenic series also serves to analyze the effects that mutations have on the development 
of a certain disease, or to test the specificity of therapeutic candidates that target mutant 





CRISPR in Public Health: Horizontal Gene Transfer 
Antibiotic-resistant pathogens are a rampant problem in hospitals around the 
world, and the conferral of antibiotic resistance in pathogens that are normally vulnerable 
to antibiotics comes from horizontal gene transfer (HGT) (Marraffini and Sontheimer, 
2008). HGT is the transfer of genes between two bacteria outside of the context of 
reproduction such as plasmid transformation, and is known to confer traits that are 
beneficial for survival under selective pressures such as immune responses of eukaryotic 
hosts or exposure to antibiotics (Gophna et al., 2015). CRISPR systems have been 
demonstrated as viable barriers to HGT, as CRISPR interference prevents the 
transformation of unencapsulated and avirulent pneumococci into strains that are 
capsulated and virulent during infection in mice (Bikard et al., 2012). Pneumococcal 
genomes do not harbor CRISPR loci, but Bikard et al. have demonstrated that 
introduction of CRISPR sequences from streptococci into S. pneumoniae results in 
prevention of DNA transformation of pneumococci. On the other hand, strong selective 
pressures for uptake of virulence and antibiotic resistance genes can result in loss of 
CRISPR protection in bacterial pathogens (Gophna et al., 2015). CRISPR loci and their 
DNA targets cannot coexist in the same host, as the introduction of CRISPR systems with 
spacers that target host chromosomal sequences results in the death of the host. In cases 
where the target DNA instills strong selective advantages such as antibiotic resistance, 
the selection survivors will have acquired the target DNA after loss of CRISPR 
interference activity or if there were mutations in the target DNA that would confer 
CRISPR interference evasion. Maintenance of genome integrity is a crucial role of 
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CRISPR systems, as HGT is a primary manner of obtaining new genetic material in 
prokaryotes (Bikard et al., 2012). On the other hand, CRISPR systems that target 
sequences with traits that are advantageous for selection may hinder the ability for the 
bacterial host to adapt and evolve under environmental selective pressures. Also, when 
CRISPR systems target sequences that confer adaptive traits, strains that possess deleted 
or inhibited CRISPR loci are selected for survival. However, these observations are only 
seen at the population level, as there is no evidence of HGT inhibition at the evolution 
level due to the mobility of CRISPR arrays, so that the presence or absence in extant 
genomes is not conclusive towards the long-term impact of CRISPR against horizontal 
gene transfer (Gophna et al., 2015). In addition, spacer acquisition is preferential towards 
new spacers from genomes that possess DNA sequences that match pre-existing spacers. 
This results in a strong bas towards sequences that are frequently encountered such as 
highly infectious viruses, as opposed to preference for the complete spectrum of 
exogenous DNA. Surveys of spacers in CRISPR arrays have shown that most of the 
matches are to prevalent archaeal viruses and bacteriophages, and numerous spacers 










Cmr Complex Mutants 
Mutant constructs of Tma Cmr have been cloned with specific mutations to 
abolish RNase or DNase activity to test how each activity is modulated by the other. The 
RNase-dead mutant has a substitution in aspartate-26 for alanine in the Cmr4 subunit, and 
the DNase-dead mutant has a substitution in histidine-32 and aspartate-33 both to 
alanines in the HD nuclease domain of the Cmr2 subunit. Another mutant construct was 
made in the GGDD motif of Cmr2 where aspartate-585 and -586 are substituted for 
alanine to shed light on ambiguous published data on the motif. These mutants will be 
tested using activity assays to ascertain the effects that abolishment of RNase or DNase 
activity has on the overall activity of the Cmr complex.  
 
Cryo-EM of Cmr Complex 
The goal of obtaining a cryo-EM structure of the Cmr complex is to determine 
how binding to target DNA activates DNase activity, as the target binding site and the 
DNase active site are distant from each other in the complex. The structure could also 
help elucidate the mechanism of determining self from nonself targets, which is also a 





Thermotoga maritima Csm1:4 and Cmr2:3 Crystallization 
Thermophilic organisms are thought to have more thermostable proteins due to 
their ability to thrive in hotter and harsher climates. These thermostable proteins are 
advantageous to protein purification and crystallization as the proteins are less liable to 
precipitate or unfold at room temperature. All currently-published structures of the 
Cmr2:3 heterodimer are from Pyrococcus furiosus (Pfu), hence the determination of 
Thermotoga maritima (Tma) Cmr2:3 could yield information on how the heterodimer 
differs across organisms, as the amino acid sequence of Cmr2:3 is not well-conserved. 
When comparing sequences between Pfu and Tma, there are sequences that correspond to 
domains in the Pfu structure that do not exist in the Tma sequence, which is useful for 





METHODS & MATERIALS 
 
Expression of Cmr Complex Subunits 
 The expression of each Cmr subunit was identical to the protocol for Csm 
subunits, but Cmr6 was exclusively tagged in Cmr complex expression and purification 
as it will not properly express without the SUMO solubility tag. After overnight 
incubation of T7 Express cells transformed with plasmid containing one of the Cmr2 – 6 
subunits, multiple colonies were picked from the lawn of T7 colonies and grown in a 
10mL overnight starter culture with the appropriate antibiotic at 37°C. 1L of LB was 
inoculated for each Cmr2 to Cmr6 subunit with 5mL of overnight starter culture and 
grown at 37°C until the optical density (OD600) of the culture reached 0.3. Upon reaching 
an OD600 of 0.3, protein expression was induced in the liter culture by addition of 200µL 
of 1M isopropyl β-D-1-thiogalactopyranoside (IPTG) and grown overnight at 20°C.  
 
Purification of Cmr Complex 
 Each individual overnight liter culture was spun down at 2,500 RPM for 45 
minutes at 4°C, followed by mixing of each cell pellet together (Estrella et al., 2016) and 
collective pellet resuspension in lysis buffer composed of 1M KCl, 20mM tris pH 8.0, 
10mM imidazole, and 1mM TCEP. For each milliliter of resuspended T7 cells, 1µL of 
each protease inhibitor was added: 100mM PMSF, 1mM E-64, 2.5mM pepstatin A, and 
1.7mM bestatin. The resuspended cells were lysed via microfluidizer followed by 
incubation of the crude cell lysate at 82°C for 10 minutes and then centrifugation of the 
incubated lysate at 18,000 RPM for 45 minutes at 20°C. After centrifugation, the 
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separated lysate supernatant was injected onto a charged IMAC column and the flow-
through was discarded. The column was then washed with 5 column volumes of lysis 
buffer, repeated at least once more until protein elution was minimal from the wash steps. 
Bound protein was eluted with 10mL of elution buffer composed of 500mM KCl, 20mM 
tris pH 8.0, 250mM imidazole, and 1mM TCEP. The IMAC eluent was then injected onto 
a HiLoad™ 26/600 Superdex™ 200pg size exclusion column equilibrated in 350mM 
KCl, 20mM tris pH 8.0, and 1mM TCEP and collected fractions corresponding to the 
appropriate protein molecular weight. 
 
Cmr1 Expression 
 After overnight incubation of T7 Express cells transformed with pHAT4-Cmr1, 
multiple colonies were picked from the lawn of T7 colonies and grown in a 10mL 
overnight starter culture with ampicillin at 37°C. 1L of LB was inoculated with 5mL of 
overnight starter culture and grown at 37°C until the OD600 of the culture reached 0.3. 
Upon reaching an OD600 of 0.3, protein expression was induced in the liter culture by 
addition of 200µL of 1M isopropyl β-D-1-thiogalactopyranoside (IPTG) and grown 
overnight at 20°C.  
 
Cmr1 Purification 
 The overnight liter culture was spun down at 2,500 RPM for 45 minutes at 4°C, 
followed resuspension of the cell pellet in lysis buffer composed of 1M KCl, 20mM tris 
pH 8.0, 10mM imidazole, and 1mM TCEP. For each milliliter of resuspended T7 cells, 
1µL of each protease inhibitor was added: 100mM PMSF, 1mM E-64, 2.5mM pepstatin 
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A, and 1.7mM bestatin. The resuspended cells were lysed via microfluidizer followed by 
incubation of the crude cell lysate at 82°C for 10 minutes and then centrifugation of the 
incubated lysate at 18,000 RPM for 45 minutes at 20°C. After centrifugation, the 
separated lysate supernatant was injected onto a charged IMAC column and the flow-
through was discarded. The column was then washed with 5 column volumes of lysis 
buffer, repeated at least once more until protein elution was minimal from the wash steps. 
Bound protein was eluted with 10mL of elution buffer composed of 500mM KCl, 20mM 
tris pH 8.0, 250mM imidazole, and 1mM TCEP. The IMAC eluent was then injected onto 
a HiPrep™ 26/10 Desalting column via FPLC and flow-through was collected 
corresponding to the protein peak in the FPLC system chromatogram. 100µL of 75µM 
SENP was added to the desalt eluent and incubated at 37°C for at least 1 hour. The SENP 
digest was then injected onto a pre-charged IMAC column and collected the tag-cleaved 
Cmr1 from the flow-through. The IMAC flow-through containing the tag-cleaved Cmr1 
was then injected onto a HiLoad™ 26/600 Superdex™ 200pg size exclusion column 
equilibrated in 350mM KCl, 20mM tris pH 8.0, and 1mM TCEP and collected fractions 
corresponding to the appropriate protein molecular weight. 
 
Purification and Crystallization of Cmr2:3 Heterodimer 
 Separate cell pellets from 3L LB cultures of each codon-optimized pSATL-Cmr2 
and codon-optimized pRSFd-Cmr3 were mixed and purified per the Cmr complex 
purification protocol, with additional steps after IMAC elution involving injection of the 
eluent onto a HiPrep™ 26/10 Desalting column via FPLC and collected flow-through 
corresponding to the protein peak in the FPLC system chromatogram. 100µL of 75µM 
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SENP was added to the desalt eluent and incubated at 37°C for at least 1 hour. The SENP 
digest was then injected onto a pre-charged IMAC column and collected the tag-cleaved 
protein from the flow-through, which was then injected onto the HiLoad™ 26/600 
Superdex™ 200pg size exclusion column. Fractions specific to the Cmr2:3 molecular 
weight were pooled and concentrated. The concentrated protein sample was then used to 
set up 96-well Qiagen JCSG+ crystallization screens at a ratio of 200nL:200nL of 
protein:condition and incubated at 20°C.  
 
Analytical Size Exclusion of Complete Cmr Complex 
 After pooling and concentrating size exclusion fractions corresponding to Cmr2-6, 
the purified complex was mixed with indicated crRNA and separately-purified Cmr1 in a 
>100µL reaction mixture. The final reaction condition contained 100mM KCl and 20mM 
tris pH 8.0, which was then incubated at 60°C for 10 minutes. The reaction mixture was 
injected onto an analytical Superose 6 Increase 10/300 GL column and collected fractions 
corresponding to the molecular weight of the full complex.  
 
Ligation-Independent Cloning: Generation of Vector Inserts 
 When studying proteins from thermophilic organisms, there are cases where it is 
unfeasible or impossible to culture the organisms through current methods, so 
recombinant expression of the proteins in E. coli is used instead as a simpler and more 
cost-efficient method. One way of creating such recombinant plasmids is through 
ligation-independent cloning (LIC), which uses linearized vectors with amplified genes 
of interest that anneal through their generated sticky ends to form recombinant plasmids 
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that express our gene of interest (Figure 5). To express the target proteins in E. coli, the 
genes from the thermophilic organisms are cloned into expression vectors and 
transformed into the E. coli expression cells. To generate LIC-compatible ends, linearized 
vector and insert were mixed with T4 DNA Polymerase to exploit its 3’-5’ exonuclease 
activity to create overhangs that are complementary to the vector or insert. A specific 
deoxynucleotide triphosphate (dNTP) was added to the reaction resulting in an 
equilibrium of 3’-5’-exonuclease and 5’-3’-polymerase activity to limit the 
exonucleolytic activity to the first complementary base. Our subunits of interest were 
either cloned into the pSATL vector with polyhistidine and small ubiquitin-like modifier 
(SUMO) tags, as well as with ampicillin antibiotic resistance genes encoded, or the 
pRSFL vector that encodes kanamycin antibiotic resistance. The 5’ overhang created on 
the gene insert anneals with the 3’ overhang of the vector which will result in an N-
terminal His-SUMO tag on genes of interest expressed in pSATL. Both pSATL and 
pRSFL are T7-inducible vectors that contain compatible origins of replication and 
antibiotic resistance genes to allow for co-transformation and resultant double antibiotic 
selection of colonies.  
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Figure 5: Schematic of generation of LIC-compatible ends and annealing of insert with 
vector (Utrecht University Department of NMR Spectroscopy, Bijvoet Center For 
Biomolecular Research).   
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Subunit Gene Amplification 
To amplify genes encoding the Csm subunits from Thermotoga maritima genomic 
DNA, primer stocks (Figure 8 and 9) were diluted to 10µM and included in the reaction 
mixture detailed in Figure 6. The GC Reaction Buffer was selected due to the high GC 
content of the primers, as other reaction buffers used for PCR resulted in failure of gene 
amplification. The following PCR protocol was used to successfully amplify each subunit 
of the Csm interference complex from Thermotoga maritima: 1 pre-cycle at 98°C for 30 
seconds, 35 denaturation cycles at 98°C for 10 seconds, anneal at 65°C for 20 seconds, 
and extend at 72°C for 15-30 seconds per kilobase pair, followed by 1 post-cycle at 72°C 
for 4 minutes, to which the reaction was then stored at 4°C until ready to collect. After 
electrophoretic separation of the PCR products, each individual band corresponding to 
the correct nucleotide length of each subunit was excised and followed manufacturer 
protocols of Thermo Scientific GeneJET Gel Extraction Kit for recovery of the insert.  
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PCR of Subunit Sequence 
Component Volume (µL) 
Deionized H2O 33 
6X GC Reaction Buffer (New 
England Biolabs) 10 
10µM Forward Primer 2.5 
10µM Reverse Primer 2.5 
200µM dNTPs 1 
Thermotoga maritima MSB8 
Genomic DNA (ATCC® 
43589D) 
0.5 
2.0 Units/µL Phusion 
Polymerase 0.5 
 
LIC pRSFL Vector 
 
LIC Subunit Insert (pRSFL) 
Component Volume (µL)  Component 
Volume 
(µL) 
Deionized H2O 11.5  Deionized H2O 9.6 








25mM dCTP 5  25mM dGTP 2 
100mM DTT 2.5  100mM DTT 1 
Gel-purified pRSFL 
Vector 25  
Gel-purified PCR 
Product 5 









Figure 6: Reaction mixtures for the PCR amplification of subunit sequences from 
genomic DNA and generation of LIC-compatible ends in pRSFL vector and in the 
subunit insert  
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LIC pSATL Vector 
 
LIC Subunit Insert (pSATL) 
Component Volume (µL)  Component 
Volume 
(µL) 
Deionized H2O 4.6  Deionized H2O 9.6 










25mM dTTP 2  25mM dATP 2 
100mM DTT 1  100mM DTT 1 
Gel-purified pSATL 
Vector 10  
Gel-purified PCR 
Product 5 










Figure 7: Reaction mixture for generation of LIC-compatible ends in pSATL vector and 











Figure 8: Sequences of primers used to PCR amplify Csm1 subunit sequence from 
Thermotoga maritima genomic DNA. Capitalized and bolded sections indicate the primer 
region that anneals to the vector, and lower case indicate the primer region that anneals to 















TmCsm5.cHis.R   ATGGTGGGATCCCGTAGATTGGGAATCTTCCAAC 
 
 
Figure 9: (Top) Sequence of pRSFL-Csm5 with C-terminal His-tag. Each region is color-
coded with the green sequence being the C-terminus of Csm5, red sequence the added 
His-tag, and blue being the pRSFL vector. (Bottom) Sequences of primers used to PCR 
amplify Csm5 subunit sequence from Thermotoga maritima genomic DNA and clone 
into pRSFL vector with an added C-terminal His-tag. Regions of annealing are 
underlined in both the primers and the construct. 
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Generation of LIC-Compatible Ends 
 To generate LIC-compatible ends in pRSFL, the vector was first linearized with 
EcoRV and the product separated from uncleaved substrates by gel electrophoresis. The 
gel band corresponding to the length of pRSFL was excised and purified to be used in the 
reaction mixture detailed in Figure 6. The reaction for generating LIC-compatible ends of 
the PCR products was similar in formulation but differs in volumes and the 
deoxynucleotide used (Figure 6). Both LIC reactions were then incubated in a 
thermocycler at 22°C for 30 minutes followed by 75°C for 20 minutes to produce LIC-
compatible ends of the vector and insert. The LICed vector and inserts were then 
combined at 2µL of LICed PCR insert with 2µL of LICed vector with 6µL of water and 
incubated at room temperature for 5 minutes, and a no-insert reaction with water instead 
of insert was prepared as a negative control. Top10 Chemically Competent E. coli cells 
(Invitrogen) were then transformed with the annealed construct, and a no-insert control 
was included as well. Transformation of Top10 cells consisted of adding 10µL of 
annealed LIC mixture to the competent cells on ice, incubation on ice for 10 minutes, 
heat shock at 42°C for 30 seconds, incubation on ice for 10 minutes again, addition of 
1mL of Luria-Bertani (LB) broth to cells and incubation at 37°C for 20 minutes, and then 
spreading of incubated cells on kanamycin resistance LB agar plates and grown overnight 
at 37°C.  
 The LIC protocol for the pSATL vector was procedurally identical to the pRSFL 
protocol with minor differences such as deoxynucleotide choice in the generation of 
single-stranded overhangs in the gene insert and the vector. First, StuI restriction enzyme 
was used instead of EcoRV for linearization of the pSATL vector, and ampicillin 
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resistance LB plates were used to grow the transformed Top10 cells instead of kanamycin. 
The LIC reaction mixtures were also different for the vector and insert, as detailed in 
Figure 7.  
To determine whether the isolated colonies growing on the resistance plates 
possess the plasmid of interest, a colony screen was performed by resuspension of 1 
picked colony in 100µL of autoclaved water, running the genomic PCR reaction but 
replacing genomic DNA stock with 0.5µL of resuspended colony, and then running the 
PCR product on an agarose gel to confirm that the band corresponds to the correct 
kilobase length.  
 
Expression of Csm Subunits 
 After transforming Top10 cells with LIC-cloned plasmids containing each Csm 
subunit, an isolated colony of Top10 cells was picked and grown in a 5mL LB culture 
with ampicillin overnight at 37°C. Using a standard minipreparation kit, plasmid was 
extracted and purified from the 5mL overnight culture, and this purified plasmid was 
used to transform T7 Express Competent E. coli cells (New England Biolabs) for protein 
expression as opposed to the plasmid maintenance Top10 strain. After overnight 
incubation, multiple colonies from the lawn of T7 colonies were taken and inoculated 
into a 10mL overnight starter culture with ampicillin at 37°C. 1L of Terrific Broth (TB) 
was then inoculated with 5-10mL of overnight starter culture and grown at 37°C until the 
optical density (OD600) of the culture reached 0.8. Upon reaching an OD600 of 0.8, protein 
expression was induced in the liter culture by addition of 1mL of 1M isopropyl β-D-1-
thiogalactopyranoside (IPTG) and grown overnight at 20°C.  
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Purification of Csm Subunits 
The overnight liter cultures were spun down at 2,500 RPM for 45 minutes at 4°C 
and the cell pellet was resuspended in lysis buffer composed of 350mM NaCl, 20mM tris 
pH 8.0, 10mM imidazole, and 10% v/v glycerol. For each milliliter of resuspended T7 
cells, 1µL of each protease inhibitor was added: 100mM phenylmethylsulfonyl fluoride 
(PMSF), 1mM proteinase inhibitor E-64, 2.5mM pepstatin A, and 1.7mM bestatin. The 
resuspended cells were lysed via microfluidizer followed by incubation of the crude cell 
lysate in an 80°C water bath for 20 minutes until lysate temperature reaches 71°C, 
followed by centrifugation of the incubated lysate at 18,000 RPM for 45 minutes at 4°C. 
To charge immobilized metal affinity chromatography (IMAC) resin for affinity 
chromatography, 100mM nickel acetate was applied to the column and the column was 
washed with at least 2 column volumes of water, followed by 5 column volumes of lysis 
buffer to equilibrate the column. After centrifugation, the separated lysate supernatant 
was injected onto the IMAC column and the flow-through was discarded. The column 
was then washed with 5 column volumes of lysis buffer to remove unbound proteins, and 
was repeated at least once more until protein elution was minimal from the wash steps. 
Bound protein was then eluted with 10mL of elution buffer composed of 350mM NaCl, 
20mM tris pH 8.0, 250mM imidazole, and 10% v/v glycerol, followed by injection of the 
eluent onto a HiPrep™ 26/10 Desalting column via fast protein liquid chromatography 
(FPLC) and flow-through was collected corresponding to the protein peak in the FPLC 
system chromatogram. 100µL of 75µM SUMO-specific protease (SENP) was added to 
the desalt eluent and incubated at 37°C for at least 1 hour to cleave His tags from the 
respective protein substrate. The SENP digest was then injected onto a pre-charged 
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IMAC column and the tag-cleaved protein collected from the flow-through, and any 
bound tagged proteins as well as bound SENP from the IMAC resin was eluted by 
flushing the column with elution buffer. The flow-through was injected onto a HiLoad™ 
26/600 Superdex™ 200pg size exclusion column equilibrated in 350mM KCl, 20mM 
HEPES pH 7.5, and 1mM tris(2-carboxyethyl)phosphine (TCEP) and certain eluted 
fractions were collected corresponding to the appropriate protein molecular weight.  
 
Purification and Crystallization of Csm1:4 Heterodimer 
 T7 Express cells were co-transformed with pSATL-Csm1 and pRSFL-Csm4 and 
grown in 6L of ampicillin/kanamycin double antibiotic Terrific Broth (TB) cultures. 
Following the Csm complex purification protocol and concentration of final size 
exclusion fractions, 25µL of 20mg/mL purified protein was produced to set up a 96-well 
Qiagen JCSG+ crystallization screen at a ratio of 200nL:200nL of protein to 







Cmr Complex Purification 
 Purification of the Cmr complex was successful based on previously-formulated 
expression and purification protocol by Michael Estrella (Estrella et al., 2016), but has 
yielded inconsistent expression of Cmr2. We then hypothesized that codon-optimizing 
the Cmr2 sequence for expression in E. coli could potentially alleviate the inconsistent 
expression issue. Codon optimization played a role in the recombinant expression of our 
proteins, as most amino acids were encoded by more than one codon triplet some 
organisms will use one codon more often than another. Purification of the Cmr complex 
involved combining cell pellets expressing each subunit, lysis by microfluidizer, 
incubation at 80°C to facilitate complex formation, followed by IMAC affinity 
chromatography and size exclusion to yield ~180µg of purified protein from 5L of LB 
(Figure 10). The consistent expression of codon-optimized Cmr2 validated our 
hypothesis that codon optimization would fix inconsistent expression issues in Cmr2. 
These mutant complexes will be used in biochemical activity assays and the D26A 
construct will also be used for cryo-EM to obtain structures of the Cmr complex bound to 
different RNA targets.   
To better understand how binding of RNA targets influence the overall 
conformation of the Cmr interference complex, RNase-deficient constructs were made. 
Aspartate-26 of Cmr4 was mutated to alanine in the D26A mutant, Cmr2 histidine-32 to 
alanine and aspartate-33 to alanine mutations were made in the HD mutant construct, and 
Cmr2 aspartate-585 as well as aspartate-586 were mutated to alanine in the GGDD palm 
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mutant. The D26A mutant was deficient in RNase activity as the catalytic residue was 
mutated, and allowed for binding of the RNA transcript without cleavage occurring 
(Ramia et al., 2014). The GGDD mutant aimed to shed light on the unknown role of the 




Figure 10: 15% SDS-PAGE gel of 2.5µM samples of Cmr2 – 6 constructs. D26A (KJ) 
prepared by Kaitlin Johnson in the Bailey lab with a Cmr6 expressed in a pHAT4 vector 
encoded a longer N-terminal His tag, compared to the His tag from pHAT2 which was 
used to express Cmr6 in the other constructs. This explained why the Cmr6 band was at a 
higher molecular weight compared to the other three constructs 
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Cryo-EM of Cmr Complex 
The goal of obtaining a cryo-EM structure of the Cmr complex was to determine 
how binding to target RNA activates DNase activity, as the target RNA binding site and 
the DNase active site are distant from each other in the complex. The structure could also 
help elucidate the mechanism of determining self from nonself targets by obtaining 
structures bound to self and nonself RNA targets. Existing crystal structures of hybrid 
Pyrococcus furiosus/Archaeoglobus fulgidus Cmr complex (Osawa et al., 2015) and 
cryo-EM structures of Thermus thermophilus Cmr complex (Taylor et al., 2015) do not 
contain the HD domain of Cmr2, and thus information on inhibition/activation of DNase 
activity cannot be deduced from existing structures of the Cmr complex. The D26A 
mutant of the Cmr complex was of importance as it allowed for binding of RNA without 
cleavage of the RNA target, as DNase activity would be turned off if the RNA target 
were to be cleaved (Estrella et al., 2016). The RNA-bound structure could then be 
compared with the unbound structure to determine any conformational changes that 
would occur after binding of the RNA target.  
Cmr complex with D26A mutation was purified and mixed with crRNA and 
Cmr1 in a 1:4:15 ratio of D26A:crRNA:Cmr1. Thermophiles like Thermotoga maritima 
grow at 80°C and exhibit the most biochemical activity at that temperature, which was 
the target temperature to incubate Cmr1 – 6 with crRNA. The mixture was incubated at 
60°C for 10 minutes to facilitate complex formation, as an 80°C incubation temperature 
resulted in precipitation of the mixture. With the goal of chromatographically separating 
the full Cmr1-6 with crRNA complex from all other mixture components, the incubated 
mixture was injected onto an analytical Superdex™ 200 Increase 10/300 GL column in a 
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buffer of 100mM KCl and 20mM tris pH 8.0, and buffers with higher salt concentrations 
resulted in weaker association of Cmr1 to the Cmr2 – 6 complex. Analytical size 
exclusion results yielded peaks corresponding to the full complex at ~10.5mL (Figure 4), 
which coeluted with a mixture of complexes containing varied stoichiometries as seen in 
the peaks between 8 and 10mL elution volume. Cmr1 presence decreased sooner than the 
other subunits across the elution volume of the full complex when the size exclusion 
buffer had a higher salt concentration (Figures 11, 12, and 13), indicating that Cmr1 
association with the complex was sensitive to salt concentration. Improved separation of 
the peaks was achieved through analytical size exclusion with a Superose 6 Increase 
10/300 GL column (Figures 14 and 15), where the peak corresponding to the full Cmr 
complex had no observable overlaps with adjacent peaks, a positive sign towards 




Figure 11: Analytical size exclusion chromatogram comparison of D26A complex at 
1:15:4 ratio of Cmr2-6:Cmr1:crRNA complexed at 200mM KCl (green trace), and 











C5 Cmr1 104.607 2.08 6.25% 0.42 
Cmr3 187.607 4.95 14.85% 1.00 
C6 Cmr1 124.607 2.48 7.32% 0.43 
Cmr3 217.192 5.73 16.90% 1.00 
C7 Cmr1 206.314 4.11 5.85% 0.32 
Cmr3 492.314 12.99 18.48% 1.00 
C8 Cmr1 442.385 8.81 6.88% 0.38 
Cmr3 875.021 23.09 18.02% 1.00 
C9 Cmr1 745.092 14.84 6.54% 0.36 
Cmr3 1568.435 41.38 18.23% 1.00 
C10 Cmr1 845.799 16.85 7.53% 0.40 
Cmr3 1611.021 42.51 19.01% 1.00 
C11 Cmr1 390.971 7.79 6.04% 0.36 
Cmr3 808.899 21.34 16.55% 1.00 
C12 Cmr1 154.899 3.09 5.81% 0.31 
Cmr3 371.728 9.81 18.48% 1.00 
D1 Cmr3 202.607 4.04 14.84% 1.00 
 
Figure 12: (Top) 15% SDS-PAGE gel of analytical size exclusion fractions of Cmr D26A 
full complex formed at 200mM KCl. (Bottom) Quantification of Cmr1 band intensity 













Cmr1 200.728 4.00 13.68% 1.03 
Cmr3 146.607 3.87 13.23% 1.00 
C4 
Cmr1 455.263 9.07 14.77% 0.98 
Cmr3 351.728 9.28 15.11% 1.00 
C5 
Cmr1 927.678 18.48 16.70% 1.09 
Cmr3 644.749 17.01 15.38% 1.00 
C6 
Cmr1 1056.263 21.04 17.08% 1.15 
Cmr3 691.556 18.25 14.81% 1.00 
C7 
Cmr1 951.263 18.95 13.42% 0.86 
Cmr3 831.971 21.95 15.55% 1.00 
C8 
Cmr1 1027.385 20.47 11.03% 0.67 
Cmr3 1151.092 30.37 16.37% 1.00 
C9 
Cmr1 1574.971 31.37 11.45% 0.66 
Cmr3 1792.971 47.31 17.26% 1.00 
C10 
Cmr1 1548.678 30.85 12.81% 0.74 
Cmr3 1577.849 41.63 17.29% 1.00 
C11 
Cmr1 905.142 18.03 12.74% 0.75 
Cmr3 913.849 24.11 17.03% 1.00 
C12 
Cmr1 748.142 14.90 17.22% 1.04 
Cmr3 541.899 14.30 16.52% 1.00 
D1 
Cmr1 739.556 14.73 29.69% 2.21 
Cmr3 252.142 6.65 13.41% 1.00 
 
Figure 13: (Top) 15% SDS-PAGE gel of analytical size exclusion fractions of Cmr D26A 
full complex formed in buffer containing 100mM KCl. (Bottom) Quantification of Cmr1 
band intensity from SDS-PAGE gel of analytical size exclusion fractions   
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Figure 14: Superose analytical size exclusion chromatogram of Cmr D26A full complex 
















Cmr1 521.385 10.39 9.72% 0.81 
Cmr3 488.435 12.89 12.07% 1.00 
D9 
Cmr1 1116.92 22.25 12.00% 0.89 
Cmr3 951.849 25.11 13.54% 1.00 
D10 
Cmr1 544.849 10.85 9.87% 0.63 
Cmr3 656.385 17.32 15.75% 1.00 
D11 
Cmr1 352.678 7.03 11.51% 0.90 
Cmr3 295.435 7.80 12.77% 1.00 
D12 
Cmr1 263.971 5.26 12.15% 1.19 
Cmr3 168.021 4.43 10.24% 1.00 
E1 
Cmr1 681.092 13.57 35.42% 4.77 
Cmr3 107.899 2.85 7.43% 1.00 
E2 
Cmr1 2331.627 46.45 67.29% 7.86 
Cmr3 224.092 5.91 8.57% 1.00 
E3 
Cmr1 2331.042 46.44 73.83% 9.69 
Cmr3 181.556 4.79 7.62% 1.00 
E4 
Cmr1 1657.335 33.01 65.07% 8.08 
Cmr3 154.849 4.09 8.05% 1.00 
E5 
Cmr1 1075.335 21.42 57.50% 18.54 
Cmr3 43.778 1.16 3.10% 1.00 
 
Figure 15: (Top) 15% SDS-PAGE of Superose analytical size exclusion fractions from 
Cmr D26A full complex formed in buffer containing 100mM KCl. (Bottom) 




Existing structures of Cmr2:3 from Pyrococcus furiosus do not contain the HD 
nuclease domain, and since the amino acid sequences of Cmr2 and Cmr3 are not well-
conserved across organisms, there was merit to crystallizing Thermotoga maritima 
Cmr2:3 to obtain information that was not available in existing structures. The D2 
domain in Pyrococcus Cmr2 makes contacts with the RNA target base-paired with the 5’ 
end of the crRNA (Figure 16). The positioning of the D2 domain could also suggest 
involvement in binding to the 3’ flanking sequence of the RNA target, which is the region 
of the target involved in self vs non-self recognition (Marraffini and Sontheimer, 2010). 
Sequence alignment of Pyrococcus and Thermotoga Cmr2 indicated that the D2 domain 
does not appear in the Thermotoga variant, which could suggest that there could be a 
different mechanism of distinguishing self vs non-self targets in Thermotoga maritima 
Cmr2. Mutagenic studies on D2 domain excision in Pyrococcus Cmr2 or D2 domain 
insertion in Thermotoga Cmr2 could potentially shed light on the functional role that the 
D2 domain plays in each organism. Codon-optimized Cmr2 expressed in pSATL and 
codon-optimized Cmr3 expressed in pRSFd are individually grown in 3L of LB each, 
where the centrifuged cell pellets were mixed, lysed, and purified together according to 
the Cmr complex protocol to form the stable Cmr2:3 heterodimer. Crystallization 
conditions from JCSG+ crystal screen yielded crystal florets from 20.35mg/mL (260/280 
= 0.56) protein sample in a 200nL:200nL ratio with crystallization solution: 0.04M 
magnesium acetate, 0.05M sodium cacodylate pH 6.0, and 30% v/v MPD. Florets of 
crystal needles formed within 3 days of crystal drop setup (Figure 17), and the largest 
needles formed at 0.04M magnesium acetate, 0.05M sodium cacodylate pH 6.2, and 28% 
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v/v MPD. Numerous crystals were sent to the Stanford Synchrotron Radiation 
Lightsource (SSRL) for data collection. The crystals diffracted x-rays to 3.0Å resolution 
and belong to space group P212121. Unfortunately, molecular replacement (performed by 
Scott Bailey) revealed that the crystals were not formed by the Cmr2:Cmr3 complex but 
by the Cmr3 subunit alone. We hypothesized that a component of the crystallization 
solution could have interfered with the heterodimer interface, or that the His-SUMO tag 
could have potentially disrupted the crystal packing mode of Cmr2:3. The heterodimer 
was then purified and the His-SUMO tag was cleaved before Qiagen JCSG+ and Nucleix 
crystallization trays were set up, and initial crystallization screens yielded ~200µm 
needle-like crystal growth in numerous conditions. The crystals that formed from the 
conditions identical to those that formed the Cmr3 crystal florets were ruled out, as they 
were likely to be only Cmr3 crystals. The other conditions that had crystal growth have 




Figure 16: Pyrococcus furiosus Cmr2 with D2 domain in orange, RNA target in yellow, 




Figure 17: (Left) crystallization tray sitting drop with crystal florets of Cmr3 at 77x 




Csm Subunit LIC Cloning 
When studying proteins from thermophilic organisms, there were cases where it 
was unfeasible or impossible to culture the organisms through current methods, so 
recombinant expression of the proteins in E. coli was used instead. To express the target 
proteins in E. coli, the genes from the thermophilic organisms were cloned into 
expression vectors and transformed into the E. coli expression cells. To clone each 
subunit of the Csm1 – 5 complex from Thermotoga maritima genomic DNA, we 
designed primers to anneal to the 15-20 nucleotides of the 5’ and 3’ ends of each Csm 
subunit and utilized polymerase chain reaction (PCR) to amplify the subunit from 
Thermotoga maritima DNA used as the PCR reaction template for the designed primers 
to anneal. We electrophoretically separated the PCR reaction products (Figure 18) and 
confirmed subunit length by its mobility on the agarose gel. Following ligation-
independent cloning, each Csm subunit was successfully incorporated into both pSATL 
and pRSFL vectors and confirmed through dideoxy Sanger sequencing. Top10 
Chemically Competent E. coli cells (Invitrogen) were chosen for transformation and 
cloning as they have recA activity silenced to reduce nonspecific recombination of cloned 
DNA, and have endA1 mutations that eliminated nonspecific cleavage by host 
endonuclease 1. These two features of the Top10 cell line helped facilitate consistent 






Figure 18: 1% agarose gel of PCR-amplified gene inserts 
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Csm Subunit Expression and Purification 
 Aside from individual subunits from other organisms, there was currently no 
published crystal structure of the Csm complex let alone from Thermotoga maritima, and 
much could be gained from analysis of the overall structure and how it compares to other 
CRISPR interference complexes. Since the expression and purification of Thermotoga 
maritima Csm subunits have not been previously performed in the lab, most of the initial 
protocols were adapted from published Cmr purification protocols (Estrella et al., 2016). 
With the goal of producing enough Csm complex to set up crystallization screens and 
perform biochemical assays, we separately expressed Csm1-5 subunits in 1L of Luria-
Bertani (LB) media and mixed the centrifuged cell pellets together, which was then lysed 
by microfluidizer. Very little Csm complex formation was observed with current 
purification protocol.  
Csm5 constructs were also designed with N-terminal and C-terminal polyhistidine 
(His) tags and LIC cloned into a pRSFL vector. This was done to determine whether the 
small ubiquitin-like modifier protein (SUMO) tag from pSATL was the cause for low 
protein concentrations after heat treatment of the crude cell lysate. We found that C-
terminally His-tagged Csm5 expressed better than N-terminal His-SUMO and N-
terminally His-tagged Csm5 constructs, which validated one of our hypotheses that the 
location of the His tag was important for expression of this subunit.  
SDS-PAGE of the immobilized metal affinity chromatography (IMAC) elution 
showed enriched presence of only the His-tagged subunit, with faint or nonexistent bands 
corresponding to untagged subunits. Purification of each Csm subunit in 6L of media 
yielded undetectable levels of untagged subunits, but the C-terminally His-tagged Csm5 
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peak isolated from size exclusion yielded 420µg of protein which was a positive 
indication that C-terminal tagging of subunits may improve protein yield after 




Figure 19: Csm complex size exclusion chromatogram, with Csm5-CHis protein peak 





Figure 20: 15% SDS-PAGE gel of Csm5-CHis size exclusion fractions   
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Csm1:4 Purification 
 Since Csm1 and Csm4 are associated together in the Csm complex, we postulated 
that they would associate when co-expressed in E. coli. Once the complex has expressed, 
we hypothesized that the complex would co-elute from IMAC affinity columns together 
as a heterodimer if one subunit was His-tagged. When Csm1 and Csm4 were separately 
expressed and then purified together, minimal heterodimer formed but expression 
improved in the purification of double-transformed T7 Express cells with Csm1 and 
Csm4 grown in LB (Figures 21 – 23). Co-transformation of the heterodimer was 
performed in other expression cells such as ArcticExpress and Rosetta™ competent cells, 
but they did not yield any appreciable improvements in expression of the subunits. Other 
medias that were richer in growth nutrients were also tested, with 2X-YT media and 
Terrific Broth (TB) producing higher yields of protein, with a preference for TB media as 
it yielded the highest amount of protein produced across the three media types tested. 
Purification of the subunits expressed by T7 cells in TB media yielded 400µg of pure 
protein with a 260/280 absorbance ratio of 0.68 which corresponded to a sample with 















Figure 23: 15% SDS-PAGE gel of Csm1:4 size exclusion fractions D8 – D12. 250µL 
aliquots of each fraction were acetone precipitated and reconstituted in water  
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Csm1:4 Crystallization 
The Thermotoga maritima Csm1:4 heterodimer was a prime target for 
crystallization and structural determination as there was no existing published structure of 
the complex, and would shed light on any structural homologies with other orthologs of 
the Cas10 – Cas5 complex. Upon expression and purification of Csm1:4 in 6L of TB 
media, 20µL of 20.48mg/mL protein was used to set up a 96-condition crystallization 
tray with Qiagen JCSG+ crystal condition screen at a ratio of 200nL:200nL 
protein:condition. Crystals formed at various conditions, with most continual growth in 
0.2M Li2SO4, 0.1M sodium acetate pH 4.5, and 30% v/v PEG8000, as well as in 0.17M 






Cmr Complex Production 
 The purification protocol of the Cmr complex had been previously formulated and 
published by Michael Estrella, but past purifications of the Cmr subunits resulted in 
inconsistent expression of Cmr2. We tested whether codon-optimizing the Cmr2 
sequence would alleviate the inconsistent expression issues, and concluded that codon 
optimization successfully alleviated the inconsistent expression issues. With the subunits 
already cloned into appropriate vectors, there were little issues and obstacles encountered 
during the expression and purification of Cmr complex mutants.  
 
Cryo-EM of Cmr Complex Mutants 
 With the goal of producing purified monodisperse Cmr complex (Cmr2-6 with 
Cmr1) with bound crRNA, a reaction mixture of each component is incubated at 60°C 
and injected onto a Superose 6 Increase 10/300 GL column to separate the full complex 
from complexes with incomplete subunit stoichiometries. An initial obstacle was getting 
Cmr1 to associate with the Cmr2-6 complex, as SDS-PAGE of analytical size exclusion 
fractions across the peak corresponding to the full complex showed that band intensity 
corresponding to Cmr1 seemed to disappear at earlier fractions compared to the other 
Cmr2-6 subunits. Reaction mixtures formed in >200mM KCl resulted in suboptimal 
Cmr1 association with the rest of the complex, but reaction mixtures with a final KCl 
concentration of 100mM resulted in markedly reduced disappearance of Cmr1 at earlier 
fractions, so it can be deduced that Cmr1 association with the Cmr2-6 complex is 
sensitive to salt concentrations with an affinity for lower salt concentrations.  
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Quantification of band intensities from SDS-PAGE of analytical size exclusion 
fractions is not an accurate method of determination of subunit dissociation, as there are 
numerous sources of error in data collection and analysis such as the qualitative nature of 
integrating band intensities from gel scans. Due to the low molecular weight of Cmr5, 
there has been recurring issues with the subunit binding Coomassie Brilliant Blue dye in 
a sub-stoichiometric manner, so quantification of Cmr5 bands stained with Coomassie is 
inaccurate in representation of true Cmr5 stoichiometry in the complex. Monodispersity 
is also hard to gauge through SDS-PAGE analysis of the fractions, as it shows the total 
intensity of each subunit in the fraction instead of the intensity of each subunit associated 
in the full crRNA-bound Cmr complex within the fraction.  
A common issue in sample preparation for cryo-EM is purifying enough protein 
to yield high concentrations of sample in a 3-5µL volume (Thompson et al., 2016), and 
since the process of producing monodisperse crRNA-bound Cmr complex involves 
numerous purification steps that inevitably reduce the final yield of purified sample, there 
are optimizations that potentially need to be made with the simplest solution being 
purification of a larger volume of cell cultures. Another issue with samples in cryo-EM is 
degradation of structural integrity of the Cmr complex, as a high vacuum is needed to 
prevent scattering of electrons by air molecules which results in disruption of aqueous 
protein sample preservation (Bai et al., 2014), a potentially serious issue that could 
increase the relative salt concentration of the Cmr complex sample and result in 
dissociation of the salt-sensitive Cmr1 subunit.  
Another factor to account for is the stability of the crRNA, as the analytical size 
exclusion chromatograms indicate some degree of nucleic acid degradation in the 
 69 
reaction mixture. Future efforts will require confirmation that the crRNA in the incubated 
complex is intact, as there are risks of incorporating truncated crRNA to the Cmr 
interference complex.  
Future efforts involve activity assays to determine whether the full complex in the 
peak contains the correct number of subunits, and to test whether the crRNA within the 
full complex is intact. 
 
Cmr2:3 Crystallization 
 The crystallization conditions that facilitated crystal floret formation of purified 
His-tagged Cmr2:3 was reproducible within an appreciable range of buffering pHs and 
percentages of MPD. Ultimately the crystals formed contained a crystal packing mode 
that could only accommodate Cmr3, and molecular replacement of the diffraction pattern 
confirmed that the crystal florets only contained Cmr3. Adding a His-tag cleavage step to 
the Cmr2:3 purification protocol has not affected the yield of pure protein after size 
exclusion chromatography, and initial screening of crystallization conditions have yielded 
crystal florets. Secondary crystallization trays will be set up with titrations of 
crystallization condition components, with the hope of sending reproducible crystals to be 
diffracted at the Stanford Synchrotron Radiation Lightsource.  
 
Csm Subunit Expression and Purification 
Although we were unsuccessful in purifying the Csm complex with our existing 
purification protocols, there is promise in greater subunit expression in TB media given 
the higher concentration of Csm1:4 heterodimer produced compared to growth in LB 
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media. The purification buffers have been adapted from existing purification protocols 
for the Type III-B Cmr complex, and there is also merit in optimization of salt and 
reducing agent concentrations as nucleic acid content is a prevalent issue in our existing 
Csm purification protocol. Another route of optimization is deciding which subunit to 
express in the pSATL vector, as we have not tried different combinations of tagged and 
untagged subunits. Codon-optimizing certain subunits that fail to express is also a viable 
future direction, as it has been successful in facilitating the consistent expression of Cmr2 
and Cmr3.  
 
Csm1:4 Purification and Crystallization 
Following Csm complex purification protocols with T7 Express cells grown in 
TB has yielded enough protein to set up one 96-well crystallization screen per 6L of TB 
grown. Although some crystals have formed in numerous conditions, there was 
restrictions in the output of secondary crystallization trays to optimize the conditions of 
each crystallization screen hit as there is a very limited amount of purified protein 
produced per 6L of TB media.  
The successful expression of the Csm1:4 heterodimer demonstrates that there is 
merit in co-transformation of subunits that are known to associate in the wild type Csm 
complex, with plans for other combinations of Csm subunits planned for the future.   
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